Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells 1,500 Shares

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Ourania Tatsis sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $524.99, for a total value of $787,485.00. Following the sale, the executive vice president directly owned 45,321 shares of the company’s stock, valued at approximately $23,793,071.79. This represents a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vertex Pharmaceuticals Price Performance

Shares of VRTX stock traded down $7.34 during midday trading on Tuesday, hitting $522.25. The company had a trading volume of 2,292,336 shares, compared to its average volume of 1,470,929. The company’s 50 day simple moving average is $449.37 and its 200 day simple moving average is $456.46. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $533.67. The stock has a market cap of $132.55 billion, a price-to-earnings ratio of 30.98, a PEG ratio of 2.26 and a beta of 0.29.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 EPS for the quarter, topping the consensus estimate of $4.24 by $0.23. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.The business had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $2.99 billion. During the same quarter in the prior year, the business earned $4.06 earnings per share. The company’s quarterly revenue was up 8.3% compared to the same quarter last year. Analysts anticipate that Vertex Pharmaceuticals Incorporated will post 17.02 EPS for the current year.

Institutional Trading of Vertex Pharmaceuticals

A number of institutional investors have recently bought and sold shares of VRTX. Motiv8 Investments LLC acquired a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth $26,000. Swiss RE Ltd. acquired a new stake in Vertex Pharmaceuticals in the 4th quarter valued at about $28,000. Eagle Bay Advisors LLC purchased a new position in Vertex Pharmaceuticals during the 4th quarter valued at about $29,000. IMG Wealth Management Inc. increased its holdings in Vertex Pharmaceuticals by 277.8% during the 4th quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock valued at $31,000 after acquiring an additional 50 shares in the last quarter. Finally, Ares Financial Consulting LLC acquired a new position in Vertex Pharmaceuticals during the fourth quarter worth about $33,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on VRTX. Oppenheimer lifted their target price on shares of Vertex Pharmaceuticals from $540.00 to $600.00 and gave the company an “outperform” rating in a report on Tuesday, March 10th. Jefferies Financial Group initiated coverage on Vertex Pharmaceuticals in a report on Tuesday, March 10th. They issued a “buy” rating and a $580.00 price objective on the stock. Bank of America boosted their target price on Vertex Pharmaceuticals from $571.00 to $598.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Maxim Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $575.00 target price for the company in a research note on Wednesday, March 18th. Finally, Barclays lifted their price target on Vertex Pharmaceuticals from $607.00 to $615.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Twenty-one investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $557.09.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex’s acquisition of Crinetics gives it access to an approved rare-disease therapy and additional late-stage pipeline assets, strengthening its growth outlook and potentially expanding annual revenue over time. Vertex to Acquire Crinetics Pharmaceuticals
• Positive Sentiment: Broader sentiment around biotech has improved, with Jim Cramer calling the sector “the hottest group in the market” and suggesting merger activity could accelerate, which may support investor enthusiasm for Vertex’s deal-making strategy. Jim Cramer Calls Biotech “The Hottest Group in the Market”
• Neutral Sentiment: Analysts and market commentary are also focusing on how the acquisition may reshape Vertex’s pipeline and valuation, with some investors weighing the strategic benefits against the size of the cash outlay. Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion
• Neutral Sentiment: A separate law-firm investigation into Crinetics’ board could add some legal noise around the transaction, but it is aimed at CRNX rather than Vertex and appears secondary to the acquisition itself. Shareholder Notice: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)
• Negative Sentiment: Some traders may view the deal size as a near-term drag on Vertex shares, since large acquisitions can pressure margins, increase integration risk, and require investors to wait for synergies to show up in results. Vertex to buy Crinetics in $10 billion deal

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.